Company · founded 2001
Virogenomics BioDevelopment (United States)
Portland, United States · virogenomics.com
- Citations, last 5 years
- 12
- Works, last 5 years
- 3
- h-index
- 6
- Scientists listed
- 0
- Grants since 2016
- 22
Grants received
2025–2027 · cooperative agreement · UG3
IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder
Jennifer M Loftis · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2024–2026 · research · R41
Immunotherapeutic Targeting CD74 as a Treatment for Stimulant Use Disorder
Jennifer M Loftis · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2024–2025 · research · R44
Paving the Way to Phase 2 Trials of CMS121 for Alzheimer's Disease
Pamela Anne Maher · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2024–2027 · cooperative agreement · U01
Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD
Pamela Anne Maher · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2024–2027 · cooperative agreement · U01
Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD
Pamela Anne Maher · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2021–2023 · research · R01
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
Pamela Anne Maher · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2021–2023 · research · R01
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
Pamela Anne Maher · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2021–2023 · research · R01
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
Pamela Anne Maher · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2021–2024 · research · R01
Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease
Pamela Anne Maher · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2019–2021 · research · R41
DRα1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder
Marilyn Huckans · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2019–2022 · research · R43
Developing novel fibrillin biomarkers for aortic disease
Jeffrey S King · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2017–2019 · research · R41
DRα1-MOG: A Novel Immunomodulatory Therapeutic for Stroke
Nabil J Alkayed · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2016–2020 · research · R42
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
Arthur A. Vandenbark · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2016–2025 · research · R44
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
Renee Lynn Shirley · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2016–2019 · research · R42
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
Arthur A. Vandenbark · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2016–2017 · research · R41
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
Arthur A. Vandenbark · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Sensitive Single Cell PhosphoCount Platform for Drug-Insensitive Cell Detection and Combination Drug Screening for Leukemia
Jeffrey S King · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2016–2023 · research · R44
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
Jeffrey S King · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2016–2023 · research · R44
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
Jeffrey S King · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2013–2021 · research · R44
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD
William C Raschke · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2013–2022 · research · R44
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD
William C Raschke · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
2013–2021 · research · R44
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD
William C Raschke · Virogenomics BioDevelopment (United States) · funded by National Institutes of Health
